TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Prospective Randomized Trial on the Use of Prothrombin Complex and Fresh Frozen Plasma in Patients With Intracerebral Hemorrhage Related to Vitamin K Antagonists
Brief Summary: Intracerebral haemorrhage (ICH) is the most feared complication in patients on vitamin K antagonists (VKA). VKA related ICH occurs 8-10 times more frequently and the mortality is 2 times higher than in non-anticoagulated patients. Mortality may rise up to 67%. The higher mortality rate may in part be due to the higher rate of haematoma expansion (HE) over a longer period after symptom onset. International guidelines recommend treatment of VKA-ICH with prothrombin complex (PCC) or fresh-frozen plasma (FFP) both in combination with Vitamin-K. But these recommendations are not based on randomized controlled trials. It is known that these drugs lower the INR, and thus it is assumed that normalization of coagulopathy may lead to haemostasis and reduction of HE. Safety and efficacy of these treatments have never been studied in a prospective controlled trial.

The investigators' questions are: How potent are PCC and FFP in normalization of the INR? What is the safety profile of each of these drugs?


Options:
A: Arm Label: Prothrombin complex concentrate (PCC); Type: EXPERIMENTAL; Interventions: Drug: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP) | Arm Label: Fresh frozen plasma (FFP); Type: EXPERIMENTAL; Interventions: Drug: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP) | Intervention Type: DRUG; Name: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP); Assigned to Arm(s): Fresh frozen plasma (FFP), Prothrombin complex concentrate (PCC)
B: Arm Label: Niastase RT; Type: ACTIVE_COMPARATOR; Interventions: Biological: rfVIIa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard saline solution | Intervention Type: BIOLOGICAL; Name: rfVIIa; Assigned to Arm(s): Niastase RT | Intervention Type: OTHER; Name: Standard saline solution; Assigned to Arm(s): Placebo
C: Arm Label: Recombinant Activated Factor VII (rFVIIa); Type: ACTIVE_COMPARATOR; Interventions: Biological: Recombinant Activated Factor VII (rFVIIa) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Recombinant Activated Factor VII (rFVIIa); Assigned to Arm(s): Recombinant Activated Factor VII (rFVIIa) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1-Recombinant activated factor VII; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant activated factor VII | Arm Label: Group 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Group 3 - Observation Only Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: recombinant activated factor VII; Assigned to Arm(s): Group 1-Recombinant activated factor VII | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group 2 - Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Clinical and Cost-effectiveness of Mindfulness Based Cognitive Therapy, Maintenance Antidepressant Medication and Its Combination in the Prevention of Relapse in Patients With Recurrent Depression
Brief Summary: The purpose of this study is to investigate the (cost)effectiveness of mindfulness based cognitive therapy (MBCT) compared to that of antidepressant medication, and its combination with regard to the prevention of relapse or recurrence in patients with recurrent depression.


Options:
A: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A
B: Arm Label: Behavioral Activation for Return to Work; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for return to work | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for return to work; Assigned to Arm(s): Behavioral Activation for Return to Work
C: Arm Label: duloxetine (cymbalta); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine (Cymbalta) | Arm Label: Placebo treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Duloxetine (Cymbalta) | Intervention Type: DRUG; Name: Duloxetine (Cymbalta); Assigned to Arm(s): Placebo treatment, duloxetine (cymbalta)
D: Arm Label: Mindfulness Based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: Combination; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy, Drug: Optimal Medical Care | Arm Label: Optimal Medical Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical Care | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): Combination, Mindfulness Based Cognitive Therapy | Intervention Type: DRUG; Name: Optimal Medical Care; Assigned to Arm(s): Combination, Optimal Medical Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Clinical and Cost-effectiveness of Mindfulness Based Cognitive Therapy, Maintenance Antidepressant Medication and Its Combination in the Prevention of Relapse in Patients With Recurrent Depression
Brief Summary: The purpose of this study is to investigate the (cost)effectiveness of mindfulness based cognitive therapy (MBCT) compared to that of antidepressant medication, and its combination with regard to the prevention of relapse or recurrence in patients with recurrent depression.


Options:
A: Arm Label: Cognitive therapy plus medications; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Therapy, Drug: Medications | Arm Label: Medications alone; Type: EXPERIMENTAL; Interventions: Drug: Medications | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive therapy plus medications | Intervention Type: DRUG; Name: Medications; Assigned to Arm(s): Cognitive therapy plus medications, Medications alone
B: Arm Label: Mindfulness Based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: Combination; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy, Drug: Optimal Medical Care | Arm Label: Optimal Medical Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical Care | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): Combination, Mindfulness Based Cognitive Therapy | Intervention Type: DRUG; Name: Optimal Medical Care; Assigned to Arm(s): Combination, Optimal Medical Care
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Non Contingent Control Condition | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Non Contingent Control Condition; Assigned to Arm(s): 2
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Specialist Mood Disorders Team | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialist Mood Disorders Team; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Clinical and Cost-effectiveness of Mindfulness Based Cognitive Therapy, Maintenance Antidepressant Medication and Its Combination in the Prevention of Relapse in Patients With Recurrent Depression
Brief Summary: The purpose of this study is to investigate the (cost)effectiveness of mindfulness based cognitive therapy (MBCT) compared to that of antidepressant medication, and its combination with regard to the prevention of relapse or recurrence in patients with recurrent depression.


Options:
A: Arm Label: Mindfulness Based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: Combination; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy, Drug: Optimal Medical Care | Arm Label: Optimal Medical Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical Care | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): Combination, Mindfulness Based Cognitive Therapy | Intervention Type: DRUG; Name: Optimal Medical Care; Assigned to Arm(s): Combination, Optimal Medical Care
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone, Drug: Escitalopram, Drug: Citalopram, Drug: Sertraline, Drug: Paroxetine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): A
C: Arm Label: Supported Protocolized Discontinuation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD) | Arm Label: SPD + Mindfulness (MBCT); Type: EXPERIMENTAL; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD), Behavioral: Mindfulness Based Cognitive Therapy (MBCT) | Intervention Type: BEHAVIORAL; Name: Supported Protocolized Discontinuation (SPD); Assigned to Arm(s): SPD + Mindfulness (MBCT), Supported Protocolized Discontinuation | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy (MBCT); Assigned to Arm(s): SPD + Mindfulness (MBCT)
D: Arm Label: CBT/Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram, Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: No CBT/escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: CBT/placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: No CBT/placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): CBT/Escitalopram, No CBT/escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CBT/placebo, No CBT/placebo | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): CBT/Escitalopram, CBT/placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)
Brief Summary: The purpose of the study is to compare the effects of one exercise/counseling protocol with usual care on long term exercise adherence and on changes in health related outcomes after breast cancer diagnosis.


Options:
A: Arm Label: Exercise Intervention Program (EIP); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Care-Management-Phone-Calls | Arm Label: Care-Management-Phone-Calls (CMPC); Type: ACTIVE_COMPARATOR; Interventions: Other: Care-Management-Phone-Calls | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention Program (EIP) | Intervention Type: OTHER; Name: Care-Management-Phone-Calls; Assigned to Arm(s): Care-Management-Phone-Calls (CMPC), Exercise Intervention Program (EIP)
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise Arm
C: Arm Label: Exercise and whole grain rye; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise, Behavioral: Whole grain rye, Behavioral: Recommendations | Arm Label: No prescriptions; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Recommendations | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise and whole grain rye | Intervention Type: BEHAVIORAL; Name: Whole grain rye; Assigned to Arm(s): Exercise and whole grain rye | Intervention Type: BEHAVIORAL; Name: Recommendations; Assigned to Arm(s): Exercise and whole grain rye, No prescriptions
D: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)
Brief Summary: The purpose of the study is to compare the effects of one exercise/counseling protocol with usual care on long term exercise adherence and on changes in health related outcomes after breast cancer diagnosis.


Options:
A: Arm Label: Arm I (Control); Type: ACTIVE_COMPARATOR; Interventions: Other: questionnaire administration, Procedure: quality-of-life assessment, Procedure: management of therapy complications | Arm Label: Arm II (Exercise); Type: EXPERIMENTAL; Interventions: Other: questionnaire administration, Procedure: quality-of-life assessment, Procedure: management of therapy complications, Behavioral: exercise intervention | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): Arm II (Exercise)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and relaxation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and physical activity | Arm Label: 4; Type: NO_INTERVENTION; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: CBT and relaxation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CBT and physical activity; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 4
C: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis
Brief Summary: The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
B: Arm Label: Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: hydroxychloroquine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1, 3
D: Arm Label: Open-Label Active Treatment Enrolled from Phase 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Open-Label Active Treatment Enrolled from Phase 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Inpatient Attending Physician Rotation Duration Study
Brief Summary: The investigators are testing the effects of a change in teaching attending physicians' rotations (from 4- to 2-week blocks) on patient outcomes (unplanned urgent visits to the health care system, inpatient mortality, and length-of-stay), the educational experiences of residents and medical students and on the quality of the professional lives of the attending physicians.


Options:
A: Arm Label: Transcendental Meditation Intervention Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Transcendental Meditation | Arm Label: Treatment as usual(TAU) Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation; Assigned to Arm(s): Transcendental Meditation Intervention Arm
B: Arm Label: 2 weeks; Type: ACTIVE_COMPARATOR; Interventions: Other: 2-week rotation | Arm Label: 4 weeks; Type: PLACEBO_COMPARATOR; Interventions: Other: 4-week rotation | Intervention Type: OTHER; Name: 2-week rotation; Assigned to Arm(s): 2 weeks | Intervention Type: OTHER; Name: 4-week rotation; Assigned to Arm(s): 4 weeks
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Corporate Athlete Resilience (CAR) Training Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Corporate Athlete Resilience (CAR) Training Program; Assigned to Arm(s): Intervention
D: Arm Label: Mindfulness-based self-care; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based self care | Arm Label: Life as usual control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-based self care; Assigned to Arm(s): Mindfulness-based self-care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Remediation in the Schizophrenia Trials Network
Brief Summary: This study will test whether a cognitive remediation program to treat people with schizophrenia can be successfully implemented in a network of research clinics.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Behavioral: Neuroadaptive cognitive training | Arm Label: Healthy Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Neuroadaptive cognitive training | Intervention Type: BEHAVIORAL; Name: Neuroadaptive cognitive training; Assigned to Arm(s): Active, Healthy Control | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): Control
B: Arm Label: Targeted Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Targeted Cognitive Training | Arm Label: Social Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Social Cognitive Training | Intervention Type: OTHER; Name: Targeted Cognitive Training; Assigned to Arm(s): Targeted Cognitive Training | Intervention Type: OTHER; Name: Social Cognitive Training; Assigned to Arm(s): Social Cognitive Training
C: Arm Label: Cognitive Remediation; Type: EXPERIMENTAL; Interventions: Drug: Cognitive Remediation | Arm Label: Cognitive activity control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cognitive Remediation; Assigned to Arm(s): Cognitive Remediation
D: Arm Label: Posit Science Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Targeted cognitive training, Behavioral: Bridging groups | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer control, Behavioral: Health and wellness groups | Intervention Type: BEHAVIORAL; Name: Targeted cognitive training; Assigned to Arm(s): Posit Science Intervention | Intervention Type: BEHAVIORAL; Name: Computer control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Bridging groups; Assigned to Arm(s): Posit Science Intervention | Intervention Type: BEHAVIORAL; Name: Health and wellness groups; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
Brief Summary: This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).


Options:
A: Arm Label: MEDI528 50 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 50 mg | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: BIOLOGICAL; Name: MEDI528 50 mg; Assigned to Arm(s): MEDI528 50 mg | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO
B: Arm Label: AMG 317 75 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 75 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: AMG 317 300 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 300 mg | Arm Label: AMG 317 150 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 75 mg; Assigned to Arm(s): AMG 317 75 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 150 mg; Assigned to Arm(s): AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 300 mg; Assigned to Arm(s): AMG 317 300 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab (MILR1444A) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab (MILR1444A); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Alair; Type: EXPERIMENTAL; Interventions: Device: Alair System | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Alair System | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Alair | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Sham

Answer: C